Keeping up FDA funding
This article was originally published in The Tan Sheet
Executive Summary
The House Sept. 24 approves a continuing resolution to fund most of the federal government, including FDA, at fiscal 2008 appropriation levels through March 6, 2009. The money available to FDA will be calculated on the basis of both the level in its 2008 appropriation and the $150 million added in a supplemental funding package (1"The Tan Sheet" July 7, 2008, In Brief). As of Sept. 26, the Senate was scheduled to vote on the measure on Sept. 27. Without the continuing resolution, funding for the government would cease Oct. 1. As March approaches, Congress likely will pass another continuing resolution to fund the government through the end of fiscal 2009, a staffer notes
You may also be interested in...
Congress’ Omnibus Language Seeks FDA Progress Reports On Spending
Members of Congress want detailed quarterly updates from FDA on how the agency uses its 2009 appropriation, according to a joint explanatory statement accompanying the omnibus spending bill
Additional FDA funds
FDA receives $150 million in additional funding for fiscal 2008 in the Supplemental Appropriations Bill of 2008, H.R. 2642, signed June 30 by President Bush. The appropriation includes $66.8 million for the Center for Food Safety and Applied Nutrition, $28 million for the Center for Drug Evaluation and Research and $12.7 million for the Center of Biologics Evaluation and Research. In an effort led by Pennsylvania Republican Arlen Specter, the Senate initially approved giving FDA $275 million in additional fiscal 2008 funding, including $125 million for food protection, but the administration vowed to veto those elevated spending levels (1"The Tan Sheet" May 26, 2008, In Brief). Meantime, House appropriators look for progress on fiscal 2009 appropriations despite partisan differences (see story, p. 9)...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.